Latest news with #BrianAbrahams
Yahoo
5 days ago
- Business
- Yahoo
RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13
BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 7, RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) and set a price target of $13.00. A scientist in a lab coat observing a line of medicine pills in a container. The same day, the company also announced the appointment of Babar Ghias as Chief Financial Officer and Head of Corporate Development. With extensive experience from his prior roles at AvenCell Therapeutics and Paragon Biosciences, the company expects his appointment to bolster BioCryst Pharmaceutical Inc.'s (NASDAQ:BCRX) leadership team and support its goals of growth acceleration and increase in value creation. Management also sees this strategic move as instrumental for BioCryst Pharmaceutical Inc.'s (NASDAQ:BCRX) financial discipline and operational excellence, supporting its optimistic growth plans. BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is a biotechnology company that provides structure-guided drug design to develop oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. While we acknowledge the potential of BCRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT
Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen Inc. (NASDAQ:BIIB) with a price target of $208.00. A patient receiving physical therapy for a neurological disease. The company reported a 6% year-over-year growth in total revenue to $2.4 billion, while GAAP diluted EPS for the quarter reached $1.64. Product revenue also rose 3% year-over-year at constant currency and 1% year-over-year at actual currency. Management is optimistic due to the transformation in the company's portfolio, with approximately 45% of the total product revenue in the quarter coming from significant medicines outside Biogen Inc.'s (NASDAQ:BIIB) MS business. Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical company that discovers, develops, and delivers advanced therapies for serious diseases worldwide. Its medicine portfolio treats multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
7 days ago
- Business
- Business Insider
PTC Therapeutics (PTCT) Gets a Buy from RBC Capital
In a report released on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on PTC Therapeutics, with a price target of $60.00. The company's shares closed yesterday at $48.74. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Abrahams covers the Healthcare sector, focusing on stocks such as Biogen, Vertex Pharmaceuticals, and Incyte. According to TipRanks, Abrahams has an average return of -2.5% and a 43.60% success rate on recommended stocks. Currently, the analyst consensus on PTC Therapeutics is a Moderate Buy with an average price target of $61.09, implying a 25.34% upside from current levels. In a report released on June 24, Wells Fargo also maintained a Buy rating on the stock with a $74.00 price target. Based on PTC Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.18 billion and a net profit of $866.56 million. In comparison, last year the company earned a revenue of $210.12 million and had a GAAP net loss of $91.58 million Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year. Most recently, in April 2025, Matthew B. Klein, the CEO of PTCT sold 2,804.00 shares for a total of $136,638.92.
Business Insider
7 days ago
- Business
- Business Insider
RBC Capital Reaffirms Their Buy Rating on BioCryst (BCRX)
RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst on July 7 and set a price target of $13.00. The company's shares closed yesterday at $9.06. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Abrahams is an analyst with an average return of -2.5% and a 43.60% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Biogen, Vertex Pharmaceuticals, and Incyte. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioCryst with a $16.75 average price target, an 84.88% upside from current levels. In a report released on June 30, Wedbush also maintained a Buy rating on the stock with a $18.00 price target.
Business Insider
7 days ago
- Business
- Business Insider
RBC Capital Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics on July 7 and set a price target of $25.00. The company's shares closed yesterday at $19.37. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Abrahams is an analyst with an average return of -2.5% and a 43.60% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Biogen, Vertex Pharmaceuticals, and Incyte. Sarepta Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $42.71, representing a 120.50% upside. In a report released on June 23, Piper Sandler also maintained a Hold rating on the stock with a $36.00 price target. Based on Sarepta Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $744.86 million and a GAAP net loss of $447.51 million. In comparison, last year the company earned a revenue of $413.46 million and had a net profit of $36.12 million
